EC Number |
Application |
Reference |
---|
1.14.11.29 | analysis |
assay for measuring the substrate hydroxylation-coupled decarboxylation of radioactive 2-oxoglutarate to radioactive carbon dioxide as a fast, efficient, and diverse method |
765339 |
1.14.11.29 | analysis |
specific protocols for the knockdown and inhibition of the HIF prolyl hydroxylases 1-3 and the asparagine hydroxylase factor-inhibiting HIF using RNA interference and hydroxylase inhibitors, respectively |
765338 |
1.14.11.29 | drug development |
the unique function of PHD2 makes it a prime target for selective inhibition leading to regulatory control of diseases such as cancer and stroke |
725647 |
1.14.11.29 | medicine |
during disc degeneration PHD2 may offer a therapeutic target to mitigate the deleterious actions of TNF-alpha, a key proinflammatory cytokine |
745336 |
1.14.11.29 | medicine |
PHD2 represents a potential contributing factor for hepatocellular carcinoma-associated erythrocytosis. Selective inhibition of PHD2 in HCC cells might be considered as a way to manage erythrocytosis in hepatocellular carcinoma (HCC) patients |
744664 |
1.14.11.29 | pharmacology |
modulation of PHD2 activity might be considered as a new way to inhibit glioblastoma progression |
744649 |